0000000000156565

AUTHOR

Martinez E

showing 3 related works from this author

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

An international perspective on hospitalized patients with viral community-acquired pneumonia

2019

Background Who should be tested for viruses in patients with community acquired pneumonia (CAP), prevalence and risk factors for viral CAP are still debated. We evaluated the frequency of viral testing, virus prevalence, risk factors and treatment coverage with oseltamivir in patients admitted for CAP. Methods Secondary analysis of GLIMP, an international, multicenter, point-prevalence study of hospitalized adults with CAP. Testing frequency, prevalence of viral CAP and treatment with oseltamivir were assessed among patients who underwent a viral swab. Univariate and multivariate analysis was used to evaluate risk factors. Results 553 (14.9%) patients with CAP underwent nasal swab. Viral CA…

PNEUMONIAMaleMultivariate analysisInternationalityPCV13 pneumococcal conjugate vaccineDatabases FactualHospitalized patientsmedicine.medical_treatmentvirusesCAD coronary artery diseaseTesting030204 cardiovascular system & hematologyMRSA methicillin resistant Staphylococcus aureusPneumònia adquirida a la comunitatRT-PCR reverse transcriptase polymerase chain reactionchemistry.chemical_compound0302 clinical medicineCommunity-acquired pneumoniaTaverne80 and overCommunity-Acquired InfectionViral030212 general & internal medicineProspective StudiesAged 80 and overRIDT rapid influenza diagnostic testCAP community-acquired pneumoniaRSV Respiratory Syncytial virusMiddle AgedICU intensive care unitCommunity-Acquired InfectionsHospitalizationNasal SwabInfectious diseasesFemaleViral swabHumanOseltamivirmedicine.medical_specialtyLogistic ModelCommunity-acquired pneumoniaViral pneumoniaCommunity acquired pneumonia; Influenza; Oseltamivir; Testing; Viral pneumonia; Viral swab; Aged; Aged 80 and over; Antiviral Agents; Community-Acquired Infections; Cross-Sectional Studies; Databases Factual; Female; Hospitalization; Humans; Influenza Human; Internationality; Logistic Models; Male; Medication Adherence; Middle Aged; Oseltamivir; Pneumonia Viral; Prospective StudiesPneumonia ViralAdmissionSettore MED/10 - Malattie Dell'Apparato RespiratorioInfluenzavirusAntiviral AgentsVirusArticleMedication AdherenceHMPV human MetapneumovirusDatabases03 medical and health sciencesLRTI lower respiratory tract infectionOseltamivirInternal medicineInfluenza HumanInternal MedicinemedicineInfluenza virusesHumansHIV Human Immunodeficiency virusPPSV23 pneumococcal polysaccharide vaccineIn patientFactualAgedMechanical ventilationAntiviral AgentCross-Sectional Studiebusiness.industryFEV1 forced expiratory volume in one secondGLIMP global initiative for methicillin-resistant Staphylococcus aureus pneumoniaESBL extended-spectrum beta-lactamasesPneumoniamedicine.diseaseInfluenzaCommunity acquired pneumoniaCI confidence intervalOR odds ratioCross-Sectional StudiesLogistic ModelschemistryCOPD chronic obstructive pulmonary diseasebusinessCommunity acquired pneumonia ; Influenza ; Oseltamivir ; Testing ; Viral pneumonia ; Viral swab
researchProduct

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are creat…

2009

Contains fulltext : 80963.pdf (Publisher’s version ) (Open Access) BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. METHODS: We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretrovir…

MaleInfectious diseases and international health [NCEBP 13]Lymphoma030312 virologyEsophageal candidiasisCohort Studies0302 clinical medicineInterquartile range030212 general & internal medicineAIDS-RelatedLymphoma AIDS-Related0303 health sciencesMortality rateProgressive multifocal leukoencephalopathyHazard ratioPrognosis3. Good healthPathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCombinationDrug Therapy CombinationFemaleInfection and autoimmunity [NCMLS 1]HumanMicrobiology (medical)Adultmedicine.medical_specialtyPrognosiAnti-HIV Agentsantiretroviral therapyInfectious DiseaseArticleAIDS-Related Opportunistic Infection03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)Drug TherapyInternal medicinemedicineHumansAIDS-defining eventProportional Hazards ModelsAIDS-Related Opportunistic Infections/diagnosis/ mortality; Acquired Immunodeficiency Syndrome/complications/diagnosis/drug; therapy/ mortality; Adult; Anti-HIV Agents/ therapeutic use; Cohort Studies; Drug Therapy; Combination; Female; Humans; Lymphoma; AIDS-Related/diagnosis/mortality; Male; Prognosis; Proportional Hazards ModelsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic Infectionsbusiness.industryProportional hazards modelPoverty-related infectious diseases [N4i 3]Anti-HIV Agentmedicine.diseasemortalityConfidence intervalImmunologyProportional Hazards ModelCohort Studiebusiness
researchProduct